Title: AsiaToday-- Eyes focused on restructruing shipping and shipbuilding business - LegoChem ranks #1 in stock report

Publication: AsiaToday/ Bo Yun Kim

Date: 1 May 2016

Summary

• LegoChem Biosciences, which is acclaimed to be the next Hanmi Pharm, has been receiving spotlight from investors for the past two weeks.

• A researcher at the Hana Financial Investment Co. said, "LegoChem has the platform technology that can lead the global industry."

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).